{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:34:26Z","timestamp":1791920066268,"version":"4.3.4"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Current options for Chagas\u2019 disease treatment are restricted to benznidazole and nifurtimox. To the best of our knowledge, no study has ever compared their tolerance in adults in a non-endemic country.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the completion rates and drug tolerance in a cohort of patients treated according to current guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>We analysed the medical records of all Chagas\u2019 disease patients aged 18\u2009years or over who started antiparasitic treatment at the Geneva University Hospitals, Switzerland, from 2008 to 2016. We recorded treatment duration and all adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 176 patients, 92 and 84 of whom received benznidazole or nifurtimox, respectively. The overall treatment completion rate was 62.5%, without a significant difference between the groups (P=0.436). Most patients (89.8%) suffered at least one adverse event. Those receiving nifurtimox had more events (6.2 versus 3.5, P&amp;lt;0.001). Mucocutaneous symptoms predominated in the benznidazole group, whereas digestive symptoms were most frequent with nifurtimox. Neuropsychiatric events frequently occurred in both groups, most notably in patients receiving nifurtimox. Arthralgia, dyspnoea, sensitive neuropathy and pruritus were independent predictors of treatment interruption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Currently recommended drug regimens for Chagas\u2019 disease are not well tolerated and entail frequent treatment discontinuation irrespective of the drug used. This highlights the need to improve treatment tolerance in adults with Chagas\u2019 disease with new therapeutic options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkz473","type":"journal-article","created":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T15:08:42Z","timestamp":1572102522000},"page":"690-696","source":"Crossref","is-referenced-by-count":85,"title":["Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas\u2019 disease"],"prefix":"10.1093","volume":"75","author":[{"given":"Yves","family":"Jackson","sequence":"first","affiliation":[{"name":"Division of Primary Care Medicine, Geneva University Hospitals and University of Geneva, Rue Gabrielle Perret Gentil 6, 1211 Geneva 14, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Wyssa","sequence":"first","affiliation":[{"name":"School of Medicine, University of Geneva, Rue Michel-Servet 1, 1206 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Chappuis","sequence":"first","affiliation":[{"name":"Division of Tropical and Humanitarian Medicine, Geneva University Hospitals and University of Geneva, Rue Gabrielle Perret Gentil 6, 1211 Geneva 14, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"key":"2020021410594622500_dkz473-B1","year":"2019"},{"key":"2020021410594622500_dkz473-B2","doi-asserted-by":"crossref","first-page":"e0003540.","DOI":"10.1371\/journal.pntd.0003540","article-title":"Prevalence of Chagas disease in Latin-American migrants living in Europe: a systematic review and meta-analysis","volume":"9","author":"Requena-Mendez","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"2020021410594622500_dkz473-B3","doi-asserted-by":"crossref","first-page":"e0005033.","DOI":"10.1371\/journal.pntd.0005033","article-title":"Estimating the burden of Chagas Disease in the United States","volume":"10","author":"Manne-Goehler","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"2020021410594622500_dkz473-B4","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/17512433.2018.1509704","article-title":"Clinical and pharmacological profile of benznidazole for treatment of Chagas disease","volume":"11","author":"Kratz","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2020021410594622500_dkz473-B5","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1590\/0037-8682-0433-2016","article-title":"Chagas disease: review of needs, neglect, and obstacles to treatment access in Latin America","volume":"50","author":"Pinheiro","year":"2017","journal-title":"Rev Soc Bras Med Trop"},{"key":"2020021410594622500_dkz473-B6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(17)31612-4","article-title":"Chagas disease","volume":"391","author":"Perez-Molina","year":"2018","journal-title":"Lancet"},{"key":"2020021410594622500_dkz473-B7","doi-asserted-by":"crossref","first-page":"724","DOI":"10.7326\/0003-4819-144-10-200605160-00006","article-title":"Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial","volume":"144","author":"Viotti","year":"2006","journal-title":"Ann Intern Med"},{"key":"2020021410594622500_dkz473-B8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijid.2018.05.019","article-title":"Course of serological tests in treated subjects with chronic Trypanosoma cruzi infection: a systematic review and meta-analysis of individual participant data","volume":"73","author":"Sguassero","year":"2018","journal-title":"Int J Infect Dis"},{"key":"2020021410594622500_dkz473-B9","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1128\/AAC.01662-13","article-title":"Towards a paradigm shift in the treatment of chronic Chagas disease","volume":"58","author":"Viotti","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021410594622500_dkz473-B10","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S1473-3099(15)00243-1","article-title":"Old and new challenges in Chagas disease","volume":"15","author":"Perez-Molina","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2020021410594622500_dkz473-B11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1087057114550585","article-title":"Chagas disease drug discovery: toward a new era","volume":"20","author":"Chatelain","year":"2015","journal-title":"J Biomol Screen"},{"key":"2020021410594622500_dkz473-B12","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/jac\/dkp357","article-title":"Use of benznidazole to treat chronic Chagas\u2019 disease: a systematic review with a meta-analysis","volume":"64","author":"Perez-Molina","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2020021410594622500_dkz473-B13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.actatropica.2009.10.023","article-title":"Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches","volume":"115","author":"Urbina","year":"2009","journal-title":"Acta Trop"},{"key":"2020021410594622500_dkz473-B14","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1086\/656917","article-title":"Tolerance and safety of nifurtimox in patients with chronic Chagas disease","volume":"51","author":"Jackson","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2020021410594622500_dkz473-B15","year":"2002"},{"key":"2020021410594622500_dkz473-B16","year":"2018"},{"key":"2020021410594622500_dkz473-B17","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1001\/jama.298.18.2171","article-title":"Evaluation and treatment of Chagas disease in the United States: a systematic review","volume":"298","author":"Bern","year":"2007","journal-title":"JAMA"},{"key":"2020021410594622500_dkz473-B18","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0140-6736(10)60061-X","article-title":"Chagas disease","volume":"375","author":"Rassi","year":"2010","journal-title":"Lancet"},{"key":"2020021410594622500_dkz473-B19","doi-asserted-by":"crossref","first-page":"19963","DOI":"10.2807\/ese.16.37.19963-en","article-title":"Chagas disease in Switzerland: history and challenges","volume":"16","author":"Jackson","year":"2011","journal-title":"Euro Surveill"},{"key":"2020021410594622500_dkz473-B20","year":"2011"},{"key":"2020021410594622500_dkz473-B21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4269\/ajtmh.2012.12-0080","article-title":"Benznidazole shortage makes Chagas disease a neglected tropical disease in developed countries: data from Spain","volume":"87","author":"Navarro","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"2020021410594622500_dkz473-B22","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4269\/ajtmh.1998.59.526","article-title":"Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas\u2019 disease","volume":"59","author":"Sosa Estani","year":"1998","journal-title":"Am J Trop Med Hyg"},{"key":"2020021410594622500_dkz473-B23","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1542\/peds.2010-1172","article-title":"Adverse events after the use of benznidazole in infants and children with Chagas disease","volume":"127","author":"Altcheh","year":"2011","journal-title":"Pediatrics"},{"key":"2020021410594622500_dkz473-B24","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/cid\/civ005","article-title":"Tolerance of benznidazole in a United States Chagas disease clinic","volume":"60","author":"Miller","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020021410594622500_dkz473-B25","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/cid\/ciw477","article-title":"Safety profile of nifurtimox for treatment of Chagas disease in the United States","volume":"63","author":"Forsyth","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020021410594622500_dkz473-B26","first-page":"123","article-title":"Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country","volume":"24","author":"Carrilero","year":"2011","journal-title":"Rev Esp Quimioter"},{"key":"2020021410594622500_dkz473-B27","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1128\/AAC.00537-10","article-title":"Tolerance of benznidazole in treatment of Chagas\u2019 disease in adults","volume":"54","author":"Pinazo","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021410594622500_dkz473-B28","first-page":"74","article-title":"Nifurtimox chemotherapy: collateral effects in treated Trypanosoma cruzi infected patients","volume":"25","author":"Murcia","year":"2012","journal-title":"Rev Esp Quimioter"},{"key":"2020021410594622500_dkz473-B29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1590\/S0036-46651996000100007","article-title":"Etiological drug treatment of human infection by Trypanosoma cruzi","volume":"38","author":"Levi","year":"1996","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"2020021410594622500_dkz473-B30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1590\/S0037-86822007000100001","article-title":"Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution","volume":"40","author":"Fabbro","year":"2007","journal-title":"Rev Soc Bras Med Trop"},{"key":"2020021410594622500_dkz473-B31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1590\/S0037-86821997000200009","article-title":"Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas\u2019 disease, in a field area with interrupted transmission. I. Preliminary evaluation","volume":"30","author":"Coura","year":"1997","journal-title":"Rev Soc Bras Med Trop"},{"key":"2020021410594622500_dkz473-B32","doi-asserted-by":"crossref","first-page":"e0185033.","DOI":"10.1371\/journal.pone.0185033","article-title":"Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease","volume":"12","author":"Olivera","year":"2017","journal-title":"PLoS One"},{"key":"2020021410594622500_dkz473-B33","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4269\/ajtmh.15-0256","article-title":"Safety profile of nifurtimox and treatment interruption for chronic Chagas disease in Colombian adults","volume":"93","author":"Olivera","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"2020021410594622500_dkz473-B34","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/AAC.01401-12","article-title":"Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic Chagas disease","volume":"57","author":"Pinazo","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021410594622500_dkz473-B35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1590\/S0074-02762002000100001","article-title":"A critical review on Chagas disease chemotherapy","volume":"97","author":"Coura","year":"2002","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"2020021410594622500_dkz473-B36","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.4269\/ajtmh.17-0044","article-title":"Benznidazole nanoformulates: a chance to improve therapeutics for Chagas disease","volume":"97","author":"Vinuesa","year":"2017","journal-title":"Am J Trop Med Hyg"},{"key":"2020021410594622500_dkz473-B37","doi-asserted-by":"crossref","first-page":"e01912-16","DOI":"10.1128\/AAC.01912-16","article-title":"Pharmacokinetics of benznidazole in healthy volunteers and implications in future clinical trials","volume":"61","author":"Molina","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021410594622500_dkz473-B38","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1128\/AAC.00745-15","article-title":"New scheme of intermittent benznidazole administration in patients chronically infected with Trypanosoma cruzi: a pilot short-term follow-up study with adult patients","volume":"60","author":"Alvarez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021410594622500_dkz473-B39","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1128\/AAC.05018-14","article-title":"Population pharmacokinetics of benznidazole in adult patients with Chagas disease","volume":"59","author":"Soy","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021410594622500_dkz473-B40","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1473-3099(17)30538-8","article-title":"Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial","volume":"18","author":"Torrico","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2020021410594622500_dkz473-B41","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1590\/0074-02760140435","article-title":"Biomarkers of therapeutic responses in chronic Chagas disease: state of the art and future perspectives","volume":"110","author":"Pinazo","year":"2015","journal-title":"Mem Inst Oswaldo Cruz"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/3\/690\/32469917\/dkz473.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/3\/690\/32469917\/dkz473.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T11:00:55Z","timestamp":1581678055000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/3\/690\/5637337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,11,21]]},"published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz473","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3]]},"published":{"date-parts":[[2019,11,21]]}}}